FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide From 503B Bulks List
Semaglutide, tirzepatide, and liraglutide just landed on the FDA’s chopping block for the 503B bulks list. The agency wants to exclude all three peptides from the list that lets outsourcing facilities compound popular research peptides in bulk. Translation: getting these GLP-1 and dual agonist compounds from compounding pharmacies could soon become a lot harder.
The Indian Practitioner
“FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide From 503B Bulks List The Indian Practitioner”
Here’s what’s changing:
The FDA’s proposal targets three of the most in-demand metabolic research peptides.
If finalized, 503B outsourcing facilities would no longer be able to use bulk semaglutide, tirzepatide, or liraglutide for compounding.
Researchers and sourcing teams may have fewer domestic options in the U.S., especially if they rely on custom formulations.
Key takeaway: The FDA isn’t banning research on semaglutide, tirzepatide, or liraglutide. But if you’re sourcing these peptides for research, expect more hurdles. This move won’t affect every supplier, but it will shift where and how U.S. researchers get these compounds.
What does this mean for the research community?
More attention on quality and sourcing from reliable vendors.
Potential for increased interest in peptide vendors outside the traditional compounding network.
A likely spike in demand for verified, well-documented research-grade peptides.
If you’re actively sourcing, now is the time to double-check your supply chain and explore alternative suppliers. The vendor directory is a good starting point if you’re looking for options or need to adapt quickly.
Regulatory decisions like this keep the peptide research community on its toes. Stay sharp and keep your sourcing flexible.
Related Reading
Saitama University researchers discover that a natural peptide aptamer switches between two target proteins depending on metal ions
News · Eur J Vasc Endovasc SurgThe STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · EIN PresswirePeptide Therapeutics Market Revenue To Cross $222 Billion By 2030 Supported By Rising Demand
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.